Study found nirmatrelvir–ritonavir did not reduce severe outcomes in vaccinated COVID-19 patients, though symptom recovery improved.

Nirmatrelvir–ritonavir does not improve severe outcomes in adults vaccinated against COVID-19

St. Michael’s Hospital’s Upstream Lab uncovers new evidence which could shape decisions on Paxlovid use for COVID-19

Studies suggest Paxlovid may not prevent severe COVID-19 outcomes in vaccinated individuals but could reduce recovery time and viral load.

If It's COVID, Paxlovid? Studies Suggest a Rethink These Days

The American College of Physicians updated outpatient COVID-19 treatment guidelines, outlining best practices for medication use in confirmed cases.

Japan approved the preventive use of the oral COVID-19 antiviral Xocova, marking the first authorization of its kind globally.